You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Intranasal, live, attenuated influenza virus vaccine reduced severe febrile illness in healthy adults

https://doi.org/10.1136/ebm.5.2.44

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (1999) JAMA 282, 137. Nichol KL, Mendelman PM, Mallon KP, et al,. for the Live Attenuated Influenza Virus Vaccine in Healthy Adults Trial Group.. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.. Jul 14;. :. –44.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: Is an intranasal, trivalent, live, attenuated influenza virus (LAIV) vaccine effective and safe for reducing febrile illness in healthy, working adults?

    Design

    Randomised (allocation not concealed*), blinded (participants and study personnel),* placebo controlled trial with follow up during site specific 7 week peak outbreak periods.

    Setting

    13 sites in the continental United States.

    Participants

    4561 people (mean age 38 y, 55% women) who were 18 to 64 years of age, worked ≥30 h/wk outside of the home, and had health insurance. Exclusion criteria included hypersensitivity to eggs, indication for or previous receipt of the inactivated vaccine, and pregnancy or unprotected risk for pregnancy in the previous 3 months. Follow up was 93%.

    Intervention

    From September 18 to November 15, 1997, 3041 participants received the LAIV vaccine …

    View Full Text

    Footnotes

    • Source of funding: Aviron.

    • For correspondence: Dr K L Nichol, Medicine Service (111), Veterans Affairs Medical Center, 1 Veterans Drive, Minneapolis, MN 55417, USA. Fax +1 612 727 5659.

    • ↵* See glossary.